Pregabalin (PRE) acts as a presynaptic inhibitor of the release of excessive levels of excitatory neurotransmitters by selectively binding to the α2-δ subunit of voltage-gated calcium channels. In this randomised, double-blind comparison trial with naltrexone (NAL), we aimed to investigate the efficacy of PRE on alcohol drinking indices. Craving reduction and improvement of psychiatric symptoms were the secondary endpoints. Seventy-one alcohol-dependent subjects were detoxified and subsequently randomised into two groups, receiving 50 mg of NAL or 150—450 mg of PRE. Craving (VAS; OCDS), withdrawal (CIWA-Ar) and psychiatric symptoms (SCL-90-R) rating scales were applied. Alcohol drinking indices and craving scores were not significantly different between groups. Compared with NAL, PRE resulted in greater improvement of specific symptoms in the areas of anxiety, hostility and psychoticism, and survival function (duration of abstinence from alcohol). PRE also resulted in better outcome in patients reporting a comorbid psychiatric disorder. Results from this study globally place PRE within the same range of efficacy as that of NAL. The mechanism involved in the efficacy of PRE in relapse prevention could be less related to alcohol craving and more associated with the treatment of the comorbid psychiatric symptomatology.
Addolorato, G., Abenavoli, L., Leggio, L., Gasbarrini, G. ( 2005) How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology51: 59-66.
2.
Ait-Daoud, N., Malcolm Jr, RJ, Johnson, BA ( 2006) An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav31: 1628-1649.
3.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, fourth ed. Text Revision. Washington, DC: American Psychiatric Association.
4.
Anton, RF, Moak, DH, Latham, P. ( 1995) The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior . Alcohol Clin Exp Res19: 92-99.
5.
Anton, RF, O’Malley, SS, Ciraulo, DA, Cisler, RA, Couper, D., Donovan, DM, et al. (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the combine study: a randomized controlled trial. JAMA95: 2003-2017.
6.
Arroyo, S., Anhut, H., Kugler, AR, Lee, CM, Knapp, LE, Garofalo, EA, et al. (2004) Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia45: 20-27.
7.
Balldin, J., Berglund, M., Borg, S., Mansson, M., Bendtsen, P., Franck, J., et al. (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioural therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res27: 1142-1149.
8.
Book, SW, Myrick, H. ( 2005) Novel anticonvulsivants in the treatment of alcoholism . Expert Opin Investig Drugs14: 371-376.
9.
Bryans, JS, Wustrow, DJ ( 1999) 3-substituted GABA analogs with central nervous system activity: a review [Review]. Med Res Rev19: 149-177.
10.
Christensen, AF, Poulsen, J., Nielsen, CT, Bork, B., Christensen, A., Christensen, M. ( 2006) Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand113: 148-153.
11.
Derogatis, LR, Lipman, RS, Covi, L. ( 1976) SCL-90: an outpatient psychiatric rating scale: preliminary report. In: Guy, W (ed), ECDEU Assessment Manual for Pychopharmacology. National Institute of Mental Health, Rockville, 320-328.
12.
Dooley, DJ, Donovan, CM, Pugsley, TA ( 2000) Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther295: 1086-1093.
13.
Driessen, M., Meier, S., Hill, A., Wetterling, T., Lange, W., Junghanns, K. ( 2001) The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol36: 249-255.
14.
Dworkin, RH, Corbin, AE, Young Jr, JP, Sharma, U., LaMoreaux, L., Bockbrader, H., et al. (2003) Pregabalin for the treatment of post-herpetic neuralgia: a randomized, placebo-controlled trial. Neurology60: 1274-1283.
15.
Feeney, GF, Connor, JP ( 2005) Review: acamprosate and naltrexone are safe and effective but have low compliance rates for people with alcohol dependence. Evid Based Ment Health8: 14.
16.
Feltner, DE, Crockatt, JG, Dubovsky, SJ, Cohn, CK, Shrivastava, RK, Targum, SD, et al. (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol23: 240-249.
17.
Feltner, D., Wittchen, HU, Kavoussi, R., Brock, J., Baldinetti, F., Pande, AC ( 2008) Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol23: 18-28.
18.
Field, MJ, Oles, RJ, Singh, L. ( 2001) Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol132: 1-4.
19.
Fink, K., Dooley, DJ, Meder, WP, Suman-Chauhan, N., Duffy, S., Clusmann, H., et al. (2002) Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology42: 229-236.
20.
Fontaine, R., Chouinard, G., Annable, L. ( 1984) Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry141: 848-852.
21.
French, JA, Kugler, AR, Robbins, JL, Knapp, LE, Garofalo, EA ( 2003) Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology60: 1631-1637.
22.
Gastfriend, DR, Garbutt, JC, Pettinati, HM, Forman, RF ( 2007) Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat33: 71-80.
23.
Gee, NS, Brown, JP, Dissanayake, VU, Offord, J., Thurlow, R., Woodruff, GN ( 1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem271: 5768-5776.
24.
Guy, W. ( 1976) ECDEU Assessment Manual for Pychopharmacology. Publication ADM 76-338. Washington, DC: US Department of Health, Education and Welfare, 218-222.
25.
Janiri, L., Calvosa, F., Dario, T., Pozzi, G., Ruggeri, A., Addolorato, G., et al. (2004) The Italian version of the Obsessive-Compulsive Drinking Scale: validation, comparison with the other versions, and difference between type 1- and type 2-like alcoholics. Drug Alcohol Depend74: 187-195.
26.
Johnson, BA, Ait-Daoud, N., Bowden, CL, DiClemente, CC, Roache, JD, Lawson, K., et al. (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet361: 1677-1685.
27.
Johnson, BA, Rosenthal, N., Capece, JA, Wiegand, F., Mao, L., Beyers, K., et al. (2007) Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA298: 1641-1651.
28.
Krystal, JH, Cramer, JA, Krol, WF, Kirk, GF, Rosenheck, RA; Veterans Affairs Naltrexone Cooperative Study 425 Group ( 2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med345: 1734-1739.
29.
Kushner, MG, Abrams, K., Thuras, P., Hanson, KL, Brekke, M., Sletten, S. ( 2005) Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcohol Clin Exp Res29: 1432-1443.
30.
Kushner, MG, Abrams, K., Thuras, P., Thuras, P., Hanson, KL ( 2000) Individual differences predictive of drinking to manage anxiety among non-problem drinkers with panic disorder. Alcohol Clin Exp Res24: 448-458.
31.
Kushner, MG, Sher, KJ, Beitman, BD ( 1990) The relation between alcohol problems and the anxiety disorders [Review]. Am J Psychiatry147: 685-695.
32.
Lejoyeux, M., Solomon, J., Ades, J. ( 1998) Benzodiazepine treatment for alcohol-dependent patients [Review]. Alcohol33: 563-575.
33.
Lesser, H., Sharma, U., LaMoreaux, L., Poole, RM ( 2004) Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology63: 2104-2110.
34.
Maneuf, YP, McKnight, AT ( 2001) Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol134: 237-240.
35.
Martinotti, G., Di Nicola, M., Tedeschi, D., Mazza, M., Janiri, L., Bria, P. ( 2008) Efficacy and safety of pregabalin in alcohol dependence . Adv Ther25: 608-618.
36.
Montgomery, SA, Tobias, K., Zornberg, GL, Kasper, S., Pande, AC ( 2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry67: 771-782.
37.
Mottola, CA ( 1993) Measurement strategies: the visual analogue scale. Decubitus6: 56-58.
38.
Pande, AC, Crockatt, JG, Feltner, DE, Janney, CA, Smith, WT, Weisler, R., et al. (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry160: 533-540.
39.
Petrakis, IL ( 2006) A rational approach to the pharmacotherapy of alcohol dependence. J Clin Psychopharmacol26 (Suppl. 1): S3-S12.
40.
Piechan, JL, Dovevan, S., Taylor, C., Dickerson, M., Li, Z. ( 2004) Pregabalin, a Novel Anticonvulsant, Analgesic, and Anxiolytic Drug, Exhibits Class-Specific Alpha2-Delta 1 and Alpha2-Delta 2 Calcium Channel Subunit Binding. Washington, DC: Society for Neuroscience. Program 115.11.2004 Abstract/itinerary Planner.
41.
Pohl, RB, Feltner, DE, Fieve, RR, Pande, AC ( 2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol25: 151-158.
42.
Randinitis, EJ, Posvar, EL, Alvey, CW, Sedman, AJ, Cook, JA, Bockbrader, HN ( 2003) Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol43: 277- 283.
43.
Rickels, K., Fox, IL, Greenblatt, DJ, Sandler, KR, Schless, A. ( 1988) Clorazepate and lorazepam: clinical improvement and rebound anxiety. Am J Psychiatry145: 312-317.
44.
Rickels, K., Pollack, MH, Feltner, DE, Lydiard, RB, Zimbroff, DL, Bielski, RJ, et al. (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry62: 1022-1030.
45.
Romach, MK, Sellers, EM, Somer, GR, Landry, M., Cunningham, GM, Jovey, RD, et al. (2002) Naltrexone in the treatment of alcohol dependence: aCanadian trial. Can J Clin Pharmacol9: 130-136.
46.
Rosenstock, J., Tuchman, M., LaMoreaux, L., Sharma, U. ( 2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain110: 628-638.
47.
Sabatowski, R., Galvez, R., Cherry, DA, Jacquot, F., Vincent, E., Maisonobe, P., et al. Versavel M.; 1008-045 Study Group (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebo-controlled clinical trial. Pain109: 26-35.
48.
Showraki, M. ( 2007) Pregabalin in the treatment of depression. J Psychopharmacol21: 883-884.
49.
Spitzer, WO, Dobson, AJ, Hall, J., Chesterman, E., Levi, J., Shepherd, R., et al. (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis34: 585-597.
50.
Srisurapanont, M., Jarusuraisin, N. ( 2005) Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol8: 267-280.
51.
Sullivan, JT, Sykora, K., Schneiderman, J., Naranjo, CA, Sellers, EM ( 1989) Assessment of alcohol withdrawal: the revised clinical Institute Withdrawal Assessment for Alcohol scale (CIWA Ar). Br J Addict84: 353-357.
52.
Volpicelli, JR, Alterman, AI, Hayashida, M., O’Brien, CP ( 1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry49: 876-880.
